Ionis nets Zanvastro US approval in first for Alexander disease
Ionis Pharmaceuticals has secured an approval from the US Food and Drug Administration (FDA) for its therapy, zilganersen, in the…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
FDA rallies HRT manufacturers amid US-wide estradiol patch shortage
The US Food and Drug Administration (FDA) has started working with six drug-device manufacturers involved in the production of transdermal…
-
Typewriter raises $56m Series A to progress non-viral gene therapy platform
Biotech startup Typewriter Therapeutics has emerged from stealth with $56m in capital as it looks to progress its non-viral in…
-
FDA cracks down on online black market for weight loss peptides
The US Food and Drug Administration (FDA) has continued its clampdown on the illegal trade of black-market peptides by issuing…
-
Trump lines up MFN deals with nine mid-size pharmas on drug pricing push
US President Donald Trump has struck a new set of Most Favored Nation (MFN) drug pricing deals with several mid-size…
-
Lilly’s Mounjaro wins US label expansion for cardiovascular risk reduction
The US Food and Drug Administration (FDA) has approved Eli Lilly’s blockbuster type 2 diabetes therapy, Mounjaro (tirzepatide), as a…
-
FDA approves Priovant’s rare autoimmune therapy Lisraya in indication first
Priovant Therapeutics has secured approval from the US Food and Drug Administration (FDA) for its oral therapy Lisraya (brepocitinib) in…
-
SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race
Biohaven and SK Pharmaceuticals have struck a licensing and partnership deal which will see the pair join forces to progress…
-
ESC 2026: Common pharma excipient linked to uptick in cardiovascular risk
A long-term analysis has revealed that high blood levels of common artificial sweetener, xylitol, can be associated with a greater…
-
GSK snags Japanese approval for first hepatitis B functional cure, Hibsago
GSK has netted the first approval globally for its chronic hepatitis B therapy, bepirovirsen, from Japan’s Ministry of Health, Labour…